Concepedia

J. Kyle Wathen

JK

Statistics

Publications

24

Citations

2.7K

H-Index

20

Active since

2003

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Memorial Sloan Kettering Cancer Center

Janssen (United States)

University of Michigan

Sarcoma Oncology Center

J. Kyle Wathen is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and biostatistics.

Publications per year

2003–2022

24

Publications

24

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel et al. · Journal of Clinical Oncology · 2007 · 733 citations

Medicine, Oncology, Pharmacology +17

Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

Rashmi Chugh, J. Kyle Wathen, Shreyaskumar Patel et al. · Clinical Cancer Research · 2010 · 237 citations · Full text

Veterinary Medicine, Oncology, Pharmacotherapy +16

Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model

Rashmi Chugh, J. Kyle Wathen, Robert G. Maki et al. · Journal of Clinical Oncology · 2009 · 234 citations · Full text

Medicine, Oncology, Pharmacology +16

Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes

Peter F. Thall, J. Kyle Wathen, B. Nebiyou Bekele et al. · Statistics in Medicine · 2003 · 205 citations

Public Health, Biostatistics, Oncology +16

Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma

Martee L. Hensley, J. Kyle Wathen, Robert G. Maki et al. · Cancer · 2013 · 171 citations · Full text

Medicine, Gynecology, Oncology +15

1–5 of 24